Blogs

Blogs

ASCOconnection.org is a forum for the exchange of views on topical issues in the field of oncology. The views expressed in the blogs, comments, and forums belong to the authors. They do not necessarily reflect the views or positions of the American Society of Clinical Oncology. Please read the Commenting Guidelines.

No Results.

I am really pleased to have with us ASCO's Chief Medical Officer and Senior Vice President for a conversation focusing on right-to-try policies.
Dr. Arjun Gupta reconsidered an order (and the evidence) for a neutropenic diet when it negatively affected his patient's quality of life.  
At the most recent Board of Directors meeting, we heard insightful presentations from participants in the Leadership Development Program, pivoted toward the execution of our 5-year strategic plan, and had a valuable conversation with NCI director Dr. Norman Sharpless.
At the most recent meeting, ASCO's delegation to the AMA House of Delegates were involved in resolutions related to Pharmacy Benefit Managers, opioids, billing for survivorship care plans, alcohol as a modifiable risk for cancer, and more.
Dr. Jaime G. de la Garza-Salazar remembers his friend and mentor on what would have been Dr. Bisel's 100th birthday.
This was a patient who needed to do cancer her way, and making it about me was not going to work.
As a pragmatic investigator and physician who has witnessed remarkable progress in the treatments we can now offer individuals with cancer, I believe the FDA’s support of more rapid and nimble testing and approval of new therapies should be applauded. 
Drs. Margaret Gatti-Mays, Kathryn Lurain, and Fatima Karzai outline how effective mentorship and social media support can help contribute to gender equity in medical leadership positions.
As Dr. Stephanie L. Graff travels home from the 2018 ASCO Annual Meeting, she finds herself literally and figuratively in the clouds.
FASCO is something earned through service to ASCO and to the field of oncology. One cannot apply or pay a fee to receive it.
As clinicians and researchers at this pivotal time in cancer research and cancer care, we need to extensively characterize our patients’ tumors, treat them with our most effective agents, and support a robust research effort to improve the efficacy of the drugs.
As the ASCO Annual Meeting approaches, I discuss the theme that I selected for the meeting and for my presidential term.
My presidential year has provided me with the chance to advocate for ASCO’s principles to support our members and our patients. 
Dr. Jane Lowe Meisel shares a first look at the program for the Women's Networking Center at the 2018 ASCO Annual Meeting. 
Dr. Edward S. Kim encourages you to register today and join the Research Community Forum in September for 2 days of learning and collaboration.
In the midst of troubles in North Africa and Middle East, we keep up with oncology education and research and keep up hope for the betterment of patient care and advancement of science in Arab countries. 
While more biosimilars will likely be available in oncology in the next several years, their specific impact on patient care is going to depend on patient and provider acceptance of these agents.
As the NSABP celebrates its 60th anniversary in 2018, Dr. Harry D. Bear honors the organization's history and accomplishments.

Pages


Advertisement